Key milestones achieved in Stereax and Goliath product lines, with initial commercial revenues and strong grant funding. EBITDA loss widened to £6.2m, but cash resources and new share placing support ongoing growth and commercialisation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.